This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / OSE Immunotherapeutics Tedopi® Phase...
Tech clinical trial results

OSE Immunotherapeutics Tedopi® Phase 2 Results

Analysis based on 6 articles · First reported Apr 23, 2026 · Last updated Apr 23, 2026

Sentiment
20
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of Tedopi®'s Phase 2 trial results being selected for an oral presentation at ASCO 2026 is a positive development for Alladapt Immunotherapeutics, potentially increasing investor confidence and its stock price. This could also signal future advancements in ovarian cancer treatment, impacting the broader biotechnology and pharmaceutical industries.

Biotechnology Pharmaceuticals
Event Summary

Alladapt Immunotherapeutics announced that topline results from its TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States, from May 29 to June 2, 2026. Alexandra Leary, Lead Investigator of the TEDOVA trial, will present the results on May 30, 2026. The TEDOVA study, sponsored by ARCAGY-GINECO, evaluates Tedopi® as a maintenance treatment, alone or in combination with Pembrolizumab® (pembrolizumab), in platinum-sensitive recurrent ovarian cancer patients.

Entities Involved
priv
Alladapt Immunotherapeutics
Alladapt Immunotherapeutics announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi® in Ovarian Cancer have been selected for an oral presentation at the 2026 ASCO Annual Meeting. This is a significant step in the development of its lead product.
Importance 100.0 Sentiment 30.0
ngo
ARCAGY-GINECO
ARCAGY-GINECO is sponsoring the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer.
Importance 60.0 Sentiment 0.0
per
Alexandra Leary
Alexandra Leary, Lead Investigator of the TEDOVA Phase 2 clinical trial of Tedopi®, will present the topline results at the ASCO 2026 Annual Meeting.
Importance 40.0 Sentiment 0.0
ngo
European Network for Gynaecological Oncological Trial groups
The TEDOVA trial is also referred to as ENGOT-ov58, indicating the involvement of the European Network for Gynaecological Oncological Trial groups (ENGOT) in the trial.
Importance 10.0 Sentiment 0.0
ngo
American Society of Clinical Oncology
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.